Skip to content
10-Q

Quarterly Report

ALNYLAM PHARMACEUTICALS, INC. ALNY

0001178670-25-000052

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 25, 2025 130.39M sh
Shares Diluted Q1 2025 · Mar 31, 2025 129.68M sh
Shares Diluted Q1 2025 · Mar 31, 2024 126.14M sh
Capex Q1 2025 · Mar 31, 2025 $8.97M
Capex Q1 2025 · Mar 31, 2024 $12.97M
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$118.31M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$81.52M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.02B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $966.43M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $681.88M
Stockholders Equity Q1 2025 · Mar 31, 2025 $115.44M
Stockholders Equity Q1 2025 · Dec 31, 2024 $67.09M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$219.27M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$220.64M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.08B
Current Liabilities Q1 2025 · Dec 31, 2024 $1.19B
Total Liabilities Q1 2025 · Mar 31, 2025 $4.1B
Total Liabilities Q1 2025 · Dec 31, 2024 $4.17B
Current Assets Q1 2025 · Mar 31, 2025 $3.27B
Current Assets Q1 2025 · Dec 31, 2024 $3.3B
Total Assets Q1 2025 · Mar 31, 2025 $4.21B
Total Assets Q1 2025 · Dec 31, 2024 $4.24B
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.44
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.52
Eps Basic Q1 2025 · Mar 31, 2025 −$0.44
Eps Basic Q1 2025 · Mar 31, 2024 −$0.52
Sga Expense Q1 2025 · Mar 31, 2025 $239.95M
Sga Expense Q1 2025 · Mar 31, 2024 $210.8M
Rd Expense Q1 2025 · Mar 31, 2025 $265.12M
Rd Expense Q1 2025 · Mar 31, 2024 $261M
Net Income Q1 2025 · Mar 31, 2025 −$57.48M
Net Income Q1 2025 · Mar 31, 2024 −$65.94M
Operating Income Q1 2025 · Mar 31, 2025 $18.08M
Operating Income Q1 2025 · Mar 31, 2024 −$43.44M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $70.18M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $54.61M
Revenue Q1 2025 · Mar 31, 2025 $594.19M
Revenue Q1 2025 · Mar 31, 2024 $494.33M